1 Title page

2	Title: Impact of COVID-19 and effects of booster vaccination with BNT162b2 on six-month
3	long COVID symptoms, quality of life, work productivity and activity impairment during
4	Omicron
5	
6	Authors: Manuela Di Fusco ^{1*} , Xiaowu Sun ² , Mary M. Moran ³ , Henriette Coetzer ² , Joann M.
7	Zamparo ⁴ , Mary B. Alvarez ⁵ , Laura Puzniak ³ , Ying P. Tabak ² , Joseph C. Cappelleri ⁶
8	
9	Affiliations:
10	¹ Pfizer Inc, Health Economics and Outcomes Research, New York, NY, USA
11	² CVS Health, Woonsocket, RI, USA
12	³ Pfizer Inc, MDSCA Vaccines, Collegeville, PA, USA
13	⁴ Pfizer Inc, Groton, CT, USA
14	⁴ Pfizer Inc, Field Medical Outcomes and Analytics, New York, NY, USA
15	⁶ Pfizer Inc, Statistical Research and Data Science Center, Groton, CT, USA
16	
17	*Corresponding author: Manuela Di Fusco
18	Health Economics and Outcomes Research
19	Pfizer, Inc., New York, NY, USA
20	Manuela.difusco@pfizer.com

21 Abstract

22	Background: Longitudinal estimates of long COVID burden during Omicron remain limited.
23	This study characterized long-term impacts of COVID-19 and booster vaccination on symptoms,
24	Health-Related Quality of Life (HRQoL), and Work Productivity Activity Impairment (WPAI).
25	
26	Methods: Outpatients with ≥ 1 self-reported symptom and positive SARS-CoV-2 test at CVS
27	Health United States test sites were recruited between 01/31-04/30/2022. Symptoms, EQ-5D and
28	WPAI were collected via online surveys until 6 months following infection. Both observed and
29	model-based estimates were analyzed. Effect sizes based on Cohen's d quantified the magnitude
30	of outcome changes over time, within and between vaccination groups. Mixed models for
31	repeated measures were conducted for multivariable analyses, adjusting for covariates. Logistic
32	regression assessed odds ratio (OR) of long COVID between vaccination groups.
33	
34	Results: At long COVID start (Week 4), 328 participants included 87 (27%) Boosted with
35	BNT162b2, 86 (26%) with a BNT162b2 primary series (Primed), and 155 (47%) Unvaccinated.
36	Mean age was 42.0 years, 73.8% were female, 26.5% had ≥1 comorbidity, 36.9% prior infection,
37	and 39.6% reported \geq 3 symptoms (mean: 3.1 symptoms). At Month 6, among 260 participants,
38	Boosted reported a mean of 1.1 symptoms versus 3.4 and 2.8 in Unvaccinated and Primed,
39	respectively (p<0.001). Boosted had reduced risks of \geq 3 symptoms versus Unvaccinated
40	(observed: OR 0.22, 95% CI, 0.10-0.47, p<0.001; model-based: OR: 0.36, 95% CI, 0.15-0.87,
41	p=0.019) and Primed (observed: OR 0.29, 95% CI, 0.13-0.67, p=0.003; model-based: OR 0.59,
42	95% CI, 0.21-1.65, p=0.459). Results were consistent using ≥ 2 symptoms. Regarding HRQoL,
43	among those with long COVID, Boosted had higher EQ-5D Utility Index (UI) than

44	Unvaccinated (observed: 0.922 versus 0.731, p=0.014; model-based: 0.910 versus 0.758, p-
45	value=0.038) and Primed (0.922 versus 0.648, p=0.014; model-based: 0.910 versus 0.708, p-
46	value=0.008). Observed and model-based estimates for EQ-VAS and UI among Boosted were
47	comparable with pre-COVID since Month 3. Subjects vaccinated generally reported better WPAI
48	scores.
49	
50	Conclusions: Long COVID negatively impacted HRQoL and WPAI. The BNT162b2 booster
51	could have a beneficial effect in reducing the risk and burden of long COVID. Boosted
52	participants reported fewer and less durable symptoms, which contributed to improve HRQoL
53	and maintain WPAI levels. Limitations included self-reported data and small sample size for
54	WPAI.
55	
56	Keywords: COVID-19; SARS-CoV-2; COVID-19 symptoms; Long COVID; BNT162b2;

57 Booster vaccine; HRQoL; WPAI.

59 Background

60 Long COVID is a broad array of complications of SARS-CoV-2 infection [1]. There is no single 61 definition of long-COVID presently and prevalence estimates vary widely across studies and 62 variants [1]. In the US, the Centers for Disease Control and Prevention (CDC) define long 63 COVID as a multitude of symptoms and conditions persisting or emerging beyond four weeks 64 after infection, and not explained by an alternative diagnosis [1]. Long COVID is found more 65 often in people who had severe COVID-19 illness, but anyone who was infected can experience 66 it [2]. While most individuals with long COVID are mildly affected and recover shortly after 67 infection, some can suffer from persistent symptoms that can affect the Health-Related Quality of Life (HRQoL) and impact daily social and professional activities [3]. 68 69 Multiple studies assessed whether vaccinated individuals are associated with a lower risk of long 70 COVID, several of them show that long COVID is less likely to occur following breakthrough 71 infection in vaccinated compared with unvaccinated individuals [4-7]. However, numerous 72 studies were conducted in selected populations that may affect generalizability [4, 5, 7, 8], 73 assessed a mix of COVID-19 vaccines, and the certainty of evidence was considered low when 74 pooling studies [6, 8]. Moreover, there is limited data on the long-term effects of COVID-19 and 75 the potential benefits of COVID-19 vaccination on symptoms, well-being, and ability to return to 76 work. 77 We aimed to address these gaps using a prospective longitudinal study design assessing long 78 COVID prevalence and levels of HRQoL and WPAI through 6 months following infection, and

- among groups defined by COVID-19 vaccination status. Our study focused on BNT162b2, the
- 80 most used COVID-19 vaccine in the US [1].

81 Methods

82 Study design and cohorts

83 The study design was previously described [9] (clinicatrials.gov NCT05160636). Briefly, this 84 was a nationwide prospective survey-based patient-reported outcomes (PRO) study targeting 85 adults \geq 18 years old with a positive reverse transcription–polymerase chain reaction (RT-PCR) 86 test result and self-reporting at least one symptom suggestive of acute SARS-CoV-2 infection at 87 time of testing [9]. The source population consisted of adults testing for SARS-CoV-2 at one of 88 ~5,000 CVS Health test sites across the US. Recruitment of consenting participants was carried 89 out between 01/31/2022 and 04/30/2022, with follow-up occurring through October 30, 2022. 90 Interim results for the acute phase (up to 4 weeks after infection) were previously presented [9]. 91 This analysis presents the final results, focusing on long-term outcomes until month 6. 92 At enrollment, we categorized the participants based on their COVID-19 vaccination history. 93 Immunocompetent participants were considered fully vaccinated with BNT162b2 if they self-94 reported receipt of 2 doses of BNT162b2 \geq 14 days prior to SARS-CoV-2 testing. They were 95 considered partially vaccinated if reporting receipt of only one of the two primary series dose, 96 and boosted if reporting receipt of at least one dose after the primary series. Participants self-97 reporting an immunocompromising condition and receipt of 3 doses were considered fully 98 vaccinated; if reporting 4 doses, they were considered boosted. Participants were considered 99 unvaccinated if they did not report any COVID-19 vaccine dose prior to testing. The study 100 population was classified in three mutually exclusive cohorts: (1) the "Primed" cohort of subjects 101 who received primary series, (2) the "Boosted" cohort of subjects with at least one dose after 102 primary series, and (3) the "Unvaccinated" cohort of subject with no evidence of vaccination. 103 Heterologous schedules were excluded (Supplemental Figure 1). To confirm vaccination status,

- 104 participants' subsequent responses to vaccination date questions were compared with their index
- 105 responses (at time of registering for testing); if responses did not match, the information was
- 106 queried and adjudicated, and the latest information was used.
- 107 Baseline characteristics and symptoms
- 108 Baseline characteristics were obtained via the CVS Health pre-test screening questionnaire.
- 109 These included self-reported demographics, comorbidities, COVID-19 vaccination history,
- 110 social determinants of health including the Social Vulnerability Index (SVI), work and/or
- 111 residency in a high-risk or healthcare setting, and symptoms [10]. The list of COVID-19
- symptoms came from the CDC's definition [11].

113 Long COVID Symptoms

114 The presence of long COVID symptoms was assessed via a questionnaire including 20

symptoms based on the 2021 CDC list [1]. The questionnaire was administered at week 4, month

116 3 and 6 after enrollment. Week 4 was considered the start of long COVID, in alignment with

117 CDC [1]. The list of symptoms included general symptoms (tiredness or fatigue, symptoms that

118 get worse after physical or mental activities, fever, general pain/discomfort), respiratory and

119 cardiac symptoms (difficulty breathing or shortness of breath, cough, chest or stomach pain, fast-

120 beating or pounding heart (also known as heart palpitations)), neurological symptoms (change in

smell or taste, headache, dizziness on standing (lightheadedness), difficulty thinking or

122 concentrating ("brain fog"), pins-and-needles feeling, sleep problems, mood changes, memory

loss), and other symptoms (diarrhea, joint or muscle pain, rash, changes in period cycles).

124 (Supplemental Figure 2).

125 Studies describing the prevalence of long COVID in the general population testing positive for

126 COVID-19 have used different thresholds for duration and intensity of symptoms [12-14].

- 127 Interim data from the CDC-funded INSPIRE Registry reported long COVID among subjects
- 128 who were symptomatic at time of testing using a cutoff of ≥ 3 symptoms at 3 months post
- 129 infection, with follow-up surveys scheduled every three months until 18 months post-enrollment
- 130 [15, 16]. Considering the similarities in the total number of symptoms assessed (~20), eligibility
- 131 criteria and study design, this study used a similar cut-off of \geq 3 symptoms, assessed 3- and 6-
- 132 months following infection
- 133 Health-Related Quality of Life
- 134 We used EQ-5D-5L to assess HRQoL [17]. Completion of the questionnaire was requested at
- enrollment, at month 1, 3 and 6 [9]. Five dimensions of EQ-5D-5L at each time point were
- 136 converted into the Utility Index (UI) using the US-based weights by Pickard et al [18]. UI and
- 137 visual analogue scale (VAS) scores were compared among cohorts and across assessment times

138 [17].

139 Work Productivity and Activity Impairment

140 To measure impairments in both paid work and unpaid work, we used the Work Productivity and

- 141 Activity Impairment General Health V2.0 (WPAI:GH) measure [19, 20]. Participants were asked
- 142 to complete the survey seven days after their RT-PCR test, at month 1, 3 and 6. Only employed
- 143 subjects were included for work productivity analyses. The WPAI results were compared across

144 cohorts and assessment times.

145 Statistical methods

146 The statistical methods were previously described [9]. Descriptive statistics were used to analyze

- 147 participant characteristics at baseline. Continuous variables were described using means and
- 148 standard deviations. Categorical variables were summarized with frequency and percentages. For
- 149 continuous variables, t-tests were used to test difference in means. Between-group differences in

150 categorical variables were tested by using chi-square statistics. When expected cell frequency 151 count was less than 5, Fisher's exact tests were used for 2-by-2 tables and Freeman-Halton tests 152 for r-by-c tables [21, 22]. Analysis of variance (ANOVA) was used to test differences in means. 153 Tukey's studentized range test was adopted for post ANOVA pairwise comparisons of means 154 between study cohorts [21, 23]. P values were all two-sided. Logistic regression model [20] was 155 used to assess the odds ratio of long COVID symptoms between study cohorts. 156 Mixed models for repeated measures (MMRM) were used to estimate the magnitude of COVID-157 19 impact on HROoL and WPAI over time [24]. Assessment time was fitted as a categorical 158 covariate and a repeated effect (repeated by subject). Least squares mean (LS mean) and 159 standard errors of PRO scores for each time point of assessment were calculated. Per guidelines, 160 no adjustment was made for missing data when scoring the EQ-5D-5L UI and WPAI [17, 20]. 161 All available data were included in the analysis. Tukey's adjustment was conducted for the comparisons of least-square means between study cohorts at each time point. 162 163 Cohen's d, or a variation of it, was calculated to assess the difference in pre-COVID scores 164 among Boosted, Primed and Unvaccinated, the magnitude of score change from baseline at 165 Week 4, Month 3 and 6 within each cohort, as well as the differences between cohorts [25, 26]. 166 Specifically, within-cohort effect size (ES) was calculated as mean change from baseline to 167 follow-up, divided by the standard deviation of change scores from baseline to follow-up [9]. 168 Between-cohort ES was calculated as the difference in mean score between cohorts, divided by 169 the pooled standard deviation of scores, or the difference in mean changes from baseline between 170 cohorts, divided by the pooled standard deviation of change scores [9]. Values of 0.2, 0.5, and 171 0.8 standard deviation (SD) units were taken represent "small," "medium," and "large" effect 172 sizes, respectively [9, 25]. All analyses were conducted with SAS Version 9.4 (SAS Institute,

- 173 Cary, NC). The study followed the Strengthening the Reporting of Observational Studies in
- 174 Epidemiology (STROBE) reporting guideline [27].

175 **Results**

176 Study population

- 177 Table 1 describes the characteristics of the 328 participants at baseline (i.e., four weeks after
- 178 infection). There were 87 (27%) Boosted, 86 (26%) Primed, and 155 (47%) Unvaccinated. There
- 179 were no subjects partially vaccinated. At Month 6, 21% (68/328) of participants dropped off.
- 180 Mean time from last dose of BNT162b2 to testing positive was 2.3 (standard deviation, SD: 1.9)
- 181 months and 6.9 (SD: 3.0) months for Boosted and Primed, respectively. The population was 42.0
- 182 years old on average, 73.8% were female, 26.5% reported ≥1 comorbidity and 36.9% were
- 183 previously infected.
- 184 The three groups generally looked similar in terms of age, gender, race, prior infection, number
- 185 of comorbidities and risk levels in workplace and household settings. Boosted participants were
- associated with less social vulnerability, with a mean SVI of 0.36 compared with 0.44 in Primed
- and 0.47 in Unvaccinated (p<0.001). Primed and Unvaccinated looked similar in terms of SVI,
- 188 comorbidities, and acute COVID-19 symptoms. Boosted reported fewer acute COVID-19
- symptoms, with a mean of 4.7 acute symptoms compared with 5.7 in Primed and 5.6 in
- 190 Unvaccinated (p=0.009). Systemic symptoms (fever, chills and muscle or body aches) and
- 191 congestion/ runny nose among Boosted were significantly lower than Primed and Unvaccinated.

192

193 Long COVID-19 risk and symptoms

194 *Time trends through Month 6*

195 Prevalence rates of long COVID-19 by assessment time and vaccination status are presented in 196 Table 2 and Supplemental Figure 3. Overall, 39.6%, 37.3% and 35.0% experienced ≥ 3 197 symptoms at Week 4, Month 3 and 6, respectively. The most prevalent symptom was 198 consistently reported to be "Fatigue or Tiredness", experienced by 41.2%, 37.3% and 38.8% at 199 Week 4, Month 3 and 6, respectively. 200 Figure 1 illustrates time trends of prevalence rates of long COVID symptoms by vaccination 201 status. Across all time points, the Boosted line appeared below and separated from the ones of 202 Unvaccinated and Primed when using the base case definition of long COVID with a cut-off of 203 \geq 3 symptoms (Figure 1a), as well as when using a cutoff of \geq 2 symptoms (Figure 1b). Figures 204 1c-1f show the prevalence rates of long COVID by body system: across all time points and 205 symptom type, the Boosted line appeared below and separated from the ones of Unvaccinated 206 and Primed. Among Boosted, declines were visible at Month 6 in Respiratory and Cardiac 207 Symptoms, General Symptoms, and Neurologic Symptoms. 208

209 From Week 4 to Month 6, noticeable improvements were observed among Boosted in several 210 symptoms, such as Tiredness or Fatigue (32.2% to 22.4%), Cough (24.1% to 0.0%), Difficulty 211 thinking or concentrating (19.5% to 7.5%), Difficulty breathing or shortness of breath (14.9% to 212 4.5%), Sleep problems (16.1% to 4.5%), and Symptoms that get worse after physical or mental 213 activities (9.2% to 1.5%). Supplemental Figures 4 and 5 illustrate, respectively, time trends of 214 the mean numbers of symptoms by vaccination status, and the proportions of participants 215 reporting no symptoms over time: the Boosted lines were consistently separated from the ones of 216 Unvaccinated and Primed.

217

218	Week	4

219	At long COVID start, participants reported a mean of 3.1 symptoms. Boosted reported fewer
220	symptoms: on average, 2.0 symptoms, significantly lower than 3.1 in Primed and 3.7 in
221	Unvaccinated (p=0.002). The prevalence of long COVID (≥3 symptoms) was 29.9%, 41.9%, and
222	43.9% among Boosted, Primed and Unvaccinated, respectively, being directionally lower in
223	Boosted (p=0.091). Relative to Unvaccinated, all symptoms' prevalence rates were numerically
224	lower in Boosted, and numerically lower or similar relative to Primed. Several symptoms were
225	significantly lower: symptoms worsening after physical or mental activities (8.5%), General
226	pain/discomfort (5.8%), Change in smell or taste (5.8%), Headache (11.5%), Memory loss
227	(4.6%), and Diarrhea (3.5%) (Table 2).
228	
229	Month 3
230	At Month 3, the prevalence of long-COVID was 23.3%, 41.6%, and 42.3% among Boosted,
231	Primed and Unvaccinated, respectively, being lowest in Boosted (p=0.016). Study participants
232	reported a mean of 2.7 symptoms. Subjects Boosted reported on average 1.4 symptoms,
233	significantly lower than 2.8 in Primed and 3.3 in Unvaccinated (p=0.001). (Table 2) All
234	symptoms' prevalence rates were numerically lower in Boosted compared to Unvaccinated and
235	Primed. Significantly lower rates were reported for Boosted for General pain/discomfort (4.1%),
236	Headache (8.2%), Dizziness on standing (lightheadedness) (4.1%), Difficulty thinking or
237	concentrating (15.1%), Sleep problems (11.0%), Mood changes (2.7%), and Memory loss (0.0%)
238	(Table 2).
239	

240 Month 6

241	At the end of the study period, the prevalence of long-COVID was 14.9%, 37.5%, and 44.6%
242	among Boosted, Primary and Unvaccinated, respectively, being lowest among Boosted
243	(p<0.001). Odds Ratios (OR) calculated based on observed data showed that pre-COVID booster
244	vaccination was associated with a reduced risk of long COVID (expressed as \geq 3 symptoms)
245	versus Unvaccinated (OR=0.22, 95% CI: 0.10-0.47, p<0.001) and Primed (OR=0.29, 95% CI:
246	0.12-0.67, p=0.003). Those Primed were associated with a non-significant reduction in the odds
247	of long COVID against Unvaccinated (OR=0.74, 95% CI: 0.41-1.35, p=0.332). The logistic
248	regression model provided a similar result of reduced odds of long COVID for Boosted versus
249	Unvaccinated (OR=0.36, 95% CI: 0.15-0.87, p=0.019), and a non-significant reduction in the
250	odds of long COVID against Primed (OR=0.59, 95% CI: 0.21-1.65, p=0.459). Similarly, a non-
251	significant reduction in the odds of long COVID was estimated for Primed versus Unvaccinated
252	(OR=0.60, 95% CI: 0.27-1.34, p=0.296). Results were consistent when using an alternative
253	definition of long COVID as ≥ 2 symptoms (Table 3).
254	Study participants reported a mean of 2.7 symptoms at 6 months. The average number of
255	symptoms was 1.1 in Boosted, significantly lower than 2.8 in Primed and 3.4 in Unvaccinated
256	(p<0.001) (Table 2). All symptoms' prevalence rates were numerically lower or similar in
257	Boosted compared with Unvaccinated and Primed. Significantly lower rates were reported in
258	Boosted for Tiredness or Fatigue (22.4%), Symptoms that get worse after physical or mental
259	activities, (1.5%), General pain/discomfort (3.0%), Difficulty breathing or shortness of breath
260	(4.5%), Cough (0.0%), Fast-beating or pounding heart (4.5%), Headache (7.5%), Difficulty
261	thinking or concentrating (7.5%), Sleep problems (4.5%), Mood changes (4.5%), Memory loss
262	(3.0%) (Table 2).

264 EQ-5D-5L

- 265 The study participants with long COVID (≥3 symptoms at Week 4, N=130) reported a pre-
- 266 COVID mean EQ-VAS and Utility Index (UI) scores of, respectively, 84.9 and 0.879 (Table 4).
- 267 Such values were not significantly different by vaccination status.
- At Week 4, the observed (Table 4) and model-based (Table 5) EQ-VAS scores were lower than
- 269 pre-COVID, regardless of vaccination status (not significantly for Primed according to the
- 270 model-based estimates). The observed EQ-VAS scores for the entire long COVID population
- were numerically similar between Week 4 (74.2) and Month 6 (74.5), and, by the end of the
- study period, they did not return to pre-COVID levels. The observed EQ-VAS scores in
- 273 Unvaccinated and Primed were still significantly lower than pre-COVID at Month 3 and 6; only
- 274 Boosted reported EQ-VAS levels not different than pre-COVID at Month 3 (p=0.266) and
- 275 Month 6 (p=0.121). The model-based EQ-VAS scores were numerically lower at Month 3 and 6
- 276 regardless of vaccination status, while not significantly different from pre-COVID, except for
- 277 Primed at Month 6 (Table 5).
- Both observed (Table 4) and model-based (Table 5) UI scores were lower than pre-COVID for
- 279 Unvaccinated and Primed for Month 3 and 6 while not different among Boosted. Consistently,
- 280 the model-based UI scores of Boosted were not different from pre-COVID at Month 3, 6 and
- since Week 4, too (Table 5).
- 282 The observed UIs values for the entire long-COVID population were numerically similar
- between Week 4 (0.74), Month 3 (0.74) and 6 (0.73) and did not return to pre-COVID levels.
- Such effect was driven by the detrimental effect of COVID-19 reported by Unvaccinated and
- 285 Primed. At Week 4, the mean UI change from pre-COVID in Boosted was significantly lower

than in Unvaccinated based on observed data and numerically lower according to model-basedestimates.

288 The mean changes in UIs from pre-COVID in Boosted were significantly lower versus

289 Unvaccinated at Month 3 and 6 based on both observed and model estimates, with medium-to-

290 high effect sizes. The mean changes from pre-COVID in UIs reported by Boosted were

significantly lower than Primed at Month 3 and 6 based on both observed and model estimates,

292 with medium-to-high effect sizes.

293 The impact of COVID-19 on the HRQoL was detrimental for participants with long COVID, but

significantly less so for Boosted, the group with the highest UI and EQ-VAS scores during the 6-

295 month study period.

296

297 WPAI

298 The WPAI analyses had a smaller eligible population and were impacted by small sample size.

A total of 85 long COVID study participants (66%) reported being currently employed at Week

300 4 and were eligible to complete the work productivity questions. Of those, 42 (49%)

301 Unvaccinated, 26 (31%) Primed and 17 (20%) Boosted.

302 Participants reported a pre-COVID mean Work Productivity (WP) loss of 15.1% (Table 4). Such

303 values were not significantly different by vaccination status. At Week 4, the observed WP loss

304 increased substantially to 31.7%. The observed WP loss scores for the entire long-COVID

305 population were numerically similar between Week 4 (31.7%), Month 3 (26.1%) and Month 6

306 (33.9%), and did not return to pre-COVID levels. Such effect was driven by the detrimental

307 effect of COVID-19 reported by Unvaccinated. At Week 4, both observed and model-based WP

308 scores were significantly lower than pre-COVID for the Unvaccinated. At Month 3 and 6, the

309	observed and model-based mean change in WP levels were not significantly different than pre-
310	COVID for Boosted and Primed (non-significant for model-based estimated for Boosted at
311	Month 6), suggesting a return to pre-COVID levels for these vaccinated groups only.
312	The long COVID study participants (N=130) reported a pre-COVID mean Activity Impairment
313	(AI) of 21.3% (Table 4). Such values were not significantly different by vaccination status. At
314	Week 4, the observed AI increased substantially to 38.1%. The observed AI scores for the entire
315	long-COVID population were numerically similar between Week 4 (38.1%), Month 3 (31.7%)
316	and Month 6 (37.5%), and did not return to pre-COVID levels. Such effect was driven by the
317	detrimental effect of COVID-19 reported by Unvaccinated, who reported the highest AI across
318	all time points. At Week 4, the mean change from pre-COVID was significantly lower than
319	Unvaccinated for Boosted and Primed based on both the observed and model-based estimates. At
320	Month 3 and Month 6, all groups were still highly impacted; subjects Boosted reported the
321	lowest AI levels.

323 Discussion

324 In this national observational study conducted among US symptomatic outpatients with a 325 documented SARS-CoV-2 infection, long COVID had a detrimental effect on well-being, work 326 productivity and activity levels. Long COVID symptoms were found persistent over 6 months in 327 over a third of the study cohort, resulting in prolonged limitation of activities and work 328 productivity. Compared with Primed and Unvaccinated, subjects Boosted with BNT162b2 prior 329 to a breakthrough infection were associated with significantly lower likelihood of long COVID 330 onset, fewer symptoms, and faster improvement over time. Positive trends in the outcomes 331 assessed were observed for Primed versus Unvaccinated, although generally not statistically 332 significant, most likely due to the relatively long mean time since last dose for Primed. The 333 prevalence of enduring symptoms after a mild COVID infection in this study was generally 334 consistent with published literature [1-5, 8]. The protective association was consistent based on 335 observed and model-based analyses and using alternative definitions of long COVID. These 336 findings support growing research and consensus that prior COVID-19 vaccination may have a 337 protective effect against long COVID [4-8]. 338

This study has several strengths compared with prior research. From a novelty perspective, this study is one of a limited number assessing diverse PROs associated with long COVID in a nationwide real-world source population. As such, it contributes a holistic picture of the longterm humanistic outcomes of COVID-19, assessed directly from a patient's perspective. From an internal validity perspective, the study enrolled patients within days from testing positive and prospectively collected survey-based data, potentially reducing recall bias risks. Moreover, the study leveraged widely used validated PRO instruments (EQ-5D-5L, WPAI) and a questionnaire capturing a comprehensive symptoms list aligned to CDC research on long COVID [1]. With

asymptomatic infections excluded by design, our estimates can be interpreted exclusively as
related to symptomatic disease, potentially reducing the risk of overestimating the prevalence of
long COVID among symptomatic. Further, both observed and model-based analyses yielded
consistent results, and our findings were robust using alternative case definitions. Finally, with
all study activities carried out virtually, this study piloted an innovative approach to agile and
digitally enabled research during a pandemic.

352 The study is subject to several limitations. As previously described [9], all data collected was 353 self-reported, subject to missingness, errors, recall bias, social desirability bias and selection bias 354 associated with survey drop-off. Out of 328 participants, 21% dropped off at Month 6, possibly 355 due to response fatigue and/or survey burden. Such drop-off rate should be interpreted in the 356 context of participants being asked not to skip surveys. Such a strict requirement allowed for a 357 clean assessment of changes in outcomes prevalence over time, but at the cost of attrition. Other 358 limitations included the female over-representation, the relatively healthy status of the source 359 population, and the fact that the study focused on adults only [9]. Further, the long COVID 360 definitions used were based on presence of symptoms, with no assessment of severity of 361 symptoms. Despite adjusting for several covariates, risk of residual confounding remains. 362 Finally, these findings may not be generalizable to prior or future variants, other countries, time 363 periods and populations that were excluded.

Booster vaccination with BNT162b2 has been shown to be safe and effective at reducing the risk of infection and potentially protective against long COVID [6, 8]; this study shows its potential beneficial effect in preventing long COVID and attenuating its burden. These outcomes can inform estimation of quality-adjusted life years and indirect costs. While this study contributes to

368	addressing	knowledge	gaps related	to long CO	VID. the chara	acterization of	f long COVID
			() · · · · · · · · · · · · · · · · · · ·				- 0

- 369 continues to evolve [28-30]. Future studies could corroborate these findings with different data
- 370 collection methods and designs, considering a non-COVID comparator, longer follow-up times,
- 371 use of COVID-19 specific validated instruments, as well as if these protective effects may
- 372 minimize impact on other individuals and households.

373 Conclusions

- 374 Long COVID had a detrimental effect on well-being, work productivity and activity levels.
- 375 Booster vaccination with BNT162b2 generally offered the highest level of protection against
- 376 long COVID. The booster was associated with less symptomatic infection and faster
- improvement, with boosted subjects experiencing the lowest number of symptoms over time.
- 378 This, in turn, contributed to improved HRQoL and maintained productivity and activities. These
- 379 findings support current recommendations for broad use of BNT162b2.

380

381 Abbreviations

- 382 ANOVA: Analysis of variance; CDC: Centers for Disease Control and Prevention; CI:
- 383 confidence interval; ES: effect size; SD: standard deviation; SVI: social vulnerability index; UI:
- 384 utility index; VAS: visual analogue scale; WPAI: work productivity and impairment.

386 **Declarations**

387 Ethics approval and consent to participate

- 388 This study was approved by the Sterling IRB, Protocol #C4591034. Participation in the study
- 389 was voluntary and anonymous. Consent was obtained electronically via the CVS Health E-
- 390 Consent platform. Participants were informed of their right to refuse or withdraw from the study
- 391 at any time. Participants were compensated for their time.
- 392 Consent for publication
- 393 All authors have given their approval for this manuscript version to be published.
- 394 Availability of data and materials
- 395 Aggregated data that support the findings of this study are available upon reasonable request
- from the corresponding author MDF, subject to review. These data are not publicly available due
- 397 to them containing information that could compromise research participant privacy/consent.
- 398 Competing interests
- 399 MDF, MMM, JMZ, LP, MBA and JCC are employees of Pfizer and may hold stock or stock
- 400 options of Pfizer. XS and HC are employees of CVS Health and may hold stock of CVS health.
- 401 YPT was employee of CVS Health when current study was conducted.
- 402 Funding
- 403 This study was sponsored by Pfizer Inc.
- 404 Author contributions
- 405 All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria
- 406 for authorship for this article. XS: Conceptualization, Methodology, Data curation, Formal
- 407 analysis, Writing original draft. MDF and YP: Investigation, Project administration,

- 408 Conceptualization, Writing Review & editing. MMM, HC, LP, MBA, and JMZ:
- 409 Conceptualization, Writing Review & editing. JCC: Conceptualization, Methodology, Formal
- 410 analysis, Writing Review & editing.

411 Acknowledgements

- 412 The authors acknowledge Nancy Gifford (Pfizer employee), Joseph Ferenchick, Shiyu Lin and
- 413 Shawn Edmonds (CVS Health employees) for specific contributions to this research project.
- 414 Editorial support was provided by Laura Anatale-Tardiff and Leena Samuel at CVS Health and
- 415 was funded by Pfizer.

416 **References**

417 1. Centers for Disease Control and Prevention. Long COVID or Post-COVID Conditions. 418 https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html Accessed August 15, 419 2022. 420 2. Ledford H (2022) How common is long COVID? Why studies give different answers. Nature. 421 606(7916):852-3. 422 Robertson M, Qasmieh S, Kulkarni S, Teasdale CA, Jones HE, McNairy M, Borrell LN, Nash D 3. 423 (2022) The epidemiology of long COVID in US adults two years after the start of the US SARS-424 CoV-2 pandemic. medRxiv. 425 4. Azzolini E, Levi R, Sarti R, Pozzi C, Mollura M, Mantovani A, Rescigno M (2022) Association 426 between BNT162b2 vaccination and long COVID after infections not requiring hospitalization in 427 health care workers. Jama. 328(7):676-8. 428 5. Al-Aly Z, Bowe B, Xie Y (2022) Long COVID after breakthrough SARS-CoV-2 infection. 429 Nature Medicine.1-7. 430 6. Notarte KI, Catahay JA, Velasco JV, Pastrana A, Ver AT, Pangilinan FC, Peligro PJ, Casimiro 431 M, Guerrero JJ, Gellaco MML (2022) Impact of COVID-19 vaccination on the risk of developing 432 long-COVID and on existing long-COVID symptoms: A systematic review. EClinicalMedicine. 433 53:101624. 434 7. Ioannou GN, Baraff A, Fox A, Shahoumian T, Hickok A, O'Hare AM, Bohnert AS, Boyko EJ, 435 Maciejewski ML, Bowling CB (2022) Rates and Factors Associated With Documentation of 436 Diagnostic Codes for Long COVID in the National Veterans Affairs Health Care System. JAMA 437 Netw Open. 5(7):e2224359. 10.1001/jamanetworkopen.2022.24359. 438 Byambasuren O, Stehlik P, Clark J (2023) Effect of covid-19 vaccination on long covid: 8. 439 systematic review. BMJ Med. 2:e000385. 440 Di Fusco M, Sun X, Moran MM, Coetzer H, Zamparo JM, Puzniak L, Alvarez MB, Tabak YP, 9. 441 Cappelleri JC (2022) Impact of COVID-19 and effects of BNT162b2 on patient-reported 442 outcomes: quality of life, symptoms, and work productivity among US adult outpatients. Journal 443 of Patient-Reported Outcomes. 6. 444 10. CDC/ATSDR Social Vulnerability Index. 445 https://www.atsdr.cdc.gov/placeandhealth/svi/index.html Accessed May 24, 2021.

446	11.	Centers for Disease Control and Prevention. Updates - Symptoms of COVID-19.
447		https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html Accessed August
448		1 2021.
449	12.	Landry M, Bornstein S, Nagaraj N, Sardon Jr GA, Castel A, Vyas A, McDonnell K, Agneshwar
450		M, Wilkinson A, Goldman L (2023) Postacute Sequelae of SARS-CoV-2 in University Setting.
451		Emerging Infectious Diseases. 29(3).
452	13.	Perlis RH, Santillana M, Ognyanova K, Safarpour A, Trujillo KL, Simonson MD, Green J,
453		Quintana A, Druckman J, Baum MA (2022) Prevalence and correlates of long COVID symptoms
454		among US adults. JAMA network open. 5(10):e2238804-e.
455	14.	O'Mahoney LL, Routen A, Gillies C, Ekezie W, Welford A, Zhang A, Karamchandani U, Simms-
456		Williams N, Cassambai S, Ardavani A (2023) The prevalence and long-term health effects of
457		Long Covid among hospitalised and non-hospitalised populations: A systematic review and meta-
458		analysis. EClinicalMedicine. 55:101762.
459	15.	Gottlieb M, Wang R, Yu H, Spatz ES, Montoy JC, Rodriguez R, Chang AM, Elmore JG,
460		Hannikainen PA, Hill M (2023) Severe Fatigue and Persistent Symptoms at Three Months
461		Following SARS-CoV-2 Infections During the Pre-Delta, Delta, and Omicron Time Periods: A
462		Multicenter Prospective Cohort Study. Clinical Infectious Diseases.ciad045.
463	16.	Spatz ES, Gottlieb M, Wisk LE, Anderson J, Chang AM, Gentile NL, Hill MJ, Huebinger RM,
464		Idris AH, Kinsman J (2022) Three-Month Symptom Profiles Among Symptomatic Adults With
465		Positive and Negative Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Tests:
466		A Prospective Cohort Study From the INSPIRE Group. Clinical Infectious Diseases.ciac966.
467	17.	EuroQol Research Foundation. (2019) EQ-5D-5L User Guide, Version 3.0.
468		https://euroqol.org/publications/user-guides Accessed August 5, 2021.
469	18.	Pickard AS, Law EH, Jiang R, Pullenayegum E, Shaw JW, Xie F, Oppe M, Boye KS, Chapman
470		RH, Gong CL, Balch A, Busschbach JJV (2019) United States Valuation of EQ-5D-5L Health
471		States Using an International Protocol. Value Health. 22(8):931-41. 10.1016/j.jval.2019.02.009.
472	19.	Reilly MC, Zbrozek AS, Dukes EM (1993) The validity and reproducibility of a work
473		productivity and activity impairment instrument. Pharmacoeconomics. 4(5):353-65.
474	20.	Reilly Associates. (2002) WPAI Scoring. http://www.reillyassociates.net/WPAI_Scoring.html
475		Accessed August 5, 2021.
476	21.	Rosner B (2015) Fundamentals of biostatistics. Eighth ed. Cengage learning, Boston, MA
477	22.	Freeman G, Halton JH (1951) Note on an exact treatment of contingency, goodness of fit and
478		other problems of significance. Biometrika. 38(1/2):141-9.
479	23.	Tukey J (1953) Multiple comparisons. Journal of the American Statistical Association.
480		48(263):624-5.
481	24.	Fitzmaurice GM, Laird NM, Ware JH (2012) Applied longitudinal analysis. John Wiley & Sons,
482		Hoboken, NJ
483	25.	Cohen J (1988) Statistical power analysis for the behavioral sciences. 2nd ed. Lawrence Erlbaum
484		Assoc, Hillsdale, NJ.
485	26.	McLeod LD, Cappelleri JC, Hays RD (2016) Best (but oft-forgotten) practices: expressing and
486		interpreting associations and effect sizes in clinical outcome assessments. The American journal
487		of clinical nutrition. 103(3):685-93. Erratum: 2017; 105:241. 2016
488		https://doi.org/10.3945/ajcn.115.120378. Erratum: 2017 https://doi.org/10.3945/ajcn.116.148593.
489	27.	STROBE Statement—Checklist of items that should be included in reports of cohort studies.
490		https://www.strobe-statement.org/download/strobe-checklist-cohort-studies-pdf Accessed August
491		5, 2022.
492	28.	Global Burden of Disease Long COVID Collaborators (2022) Estimated Global Proportions of
493		Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following
494		Symptomatic COVID-19 in 2020 and 2021. JAMA. 328(16):1604-15. 10.1001/jama.2022.18931.

- 495 29. Lubell J. (2022) Long COVID: Over 200 symptoms, and a search for guidance. <u>https://www.ama-assn.org/delivering-care/public-health/long-covid-over-200-symptoms-and-search-guidance</u>
 497 Accessed December 27, 2022.
- 498 30. World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. <u>https://www.who.int/publications/i/item/WHO-2019-nCoV-</u>
 500 Post_COVID-19_condition-Clinical_case_definition-2021.1 Accessed December 27, 2022.

501

503	List	of	Tabl	les

504	Table 1 Baseline Demographic and Clinical Characteristics of Study Participants at Week 4 24
505	Table 2. Summary of Post-COVID-19 Symptoms at 1-, 3- and 6-month follow-up
506	Table 3. Long COVID Symptoms at Month 6 by Vaccination Status: Observed and Model-based
507	Estimates
508	Table 4. Summary of Observed EQ-5D-5L and WPAI scores by assessment time and vaccination
509	status in long COVID subjects
510	Table 5. Least-Square Mean Estimates and 95% CI of EQ-5D-5L and WPAI-GH scores in long
511	COVID subjects
512	
513	List of Figures
514	Figure 1. Trajectory of prevalence of long COVID over time, by vaccination status and type37
515	
516	List of Supplemental Figures
517	Supplemental Figure 1 Study Flow Chart
518	Supplemental Figure 2 Questionnaire on long COVID symptoms
519	Supplemental Figure 3 Prevalence of long COVID symptoms by vaccination status40
520	Supplemental Figure 4 Number of symptoms over time by vaccination status
521	Supplemental Figure 5 Absence of long COVID symptoms by vaccination status
522	

	All	Boosted	Primed	Unvaccinated	P value ^a
Total, n (%)	328	87 (26.5)	86 (26.2)	155 (47.3)	
Age, years					
Mean, SD	42.0 (14.5)	44.3 (17.0)	41.7 (14.2)	40.9 (13.0)	0.200
18-29	73 (22.3%)	18 (20.7%)	23 (26.7%)	32 (20.6%)	0.110
30-49	160 (48.8%)	40 (46.0%)	34 (39.5%)	86 (55.5%)	
50-64	67 (20.4%)	17 (19.5%)	23 (26.7%)	27 (17.4%)	
≥65	28 (8.5%)	12 (13.8%)	6 (7.0%)	10 (6.5%)	
Gender					0.165
Female	242 (73.8%)	58 (66.7%)	68 (79.1%)	116 (74.8%)	
Male	86 (26.2%)	29 (33.3%)	18 (20.9%)	39 (25.2%)	
Race / Ethnicity					0.104
White or Caucasian (not Hispanic or Latino)	234 (71.3%)	63 (72.4%)	65 (75.6%)	106 (68.4%)	
Black or African American	13 (4.0%)	2 (2.3%)	2 (2.3%)	9 (5.8%)	
Hispanic	44 (13.4%)	9 (10.3%)	16 (18.6%)	19 (12.3%)	
Asian	16 (4.9%)	7 (8.1%)	2 (2.3%)	7 (4.5%)	
Patient Refused	9 (2.7%)	4 (4.6%)	0 (0.0%)	5 (3.2%)	
Other	12 (3.7%)	2 (2.3%)	1 (1.2%)	9 (5.8%)	
CMS Geographic Region (n, %)					0.009
Region 1: ME, NH, VT, MA, CT, RI	15 (4.6%)	4 (4.6%)	4 (4.7%)	7 (4.5%)	
Region 2: NY, NJ, PR, VI	9 (2.7%)	4 (4.6%)	2 (2.3%)	3 (1.9%)	
Region 3: PA, DE, MD, DC, WV, VA	31 (9.5%)	11 (12.6%)	8 (9.3%)	12 (7.7%)	
Region 4: KY, TN, NC, SC, GA, MS, AL, FL	116 (35.4%)	29 (33.3%)	26 (30.2%)	61 (39.4%)	
Region 5: MN, WI, IL, MI, IN, OH	47 (14.3%)	10 (11.5%)	17 (19.8%)	20 (12.9%)	
Region 6: NM, OK, AR, TX, LA	59 (18.0%)	19 (21.8%)	21 (24.4%)	19 (12.3%)	
Region 7: NE, IA, KS, MO	16 (4.9%)	3 (3.5%)	6 (7.0%)	7 (4.5%)	
Region 8: MT, ND, SD, WY, UT, CO	1 (0.3%)	1 (1.2%)	0 (0.0%)	0 (0.0%)	
Region 9: CA, NV, AZ, GU	33 (10.1%)	5 (5.8%)	2 (2.3%)	26 (16.8%)	
Region 10: AK, WA, OR, ID	1 (0.3%)	1 (1.2%)	0 (0.0%)	0 (0.0%)	
US Geographic Region					0.012
Northeast	41 (12.5%)	11 (12.6%)	11 (12.8%)	19 (12.3%)	
South	188 (57.3%)	56 (64.4%)	50 (58.1%)	82 (52.9%)	
Midwest	63 (19.2%)	13 (14.9%)	23 (26.7%)	27 (17.4%)	
West	36 (11.0%)	7 (8.1%)	2 (2.3%)	27 (17.4%)	
Previously Tested Positive	121 (36.9%)	32 (36.8%)	28 (32.6%)	61 (39.4%)	0.578

524 Table 1 Baseline Demographic and Clinical Characteristics of Study Participants at Week 4

	All	Boosted	Primed	Unvaccinated	P value ^a
Work in healthcare	37 (11.3%)	9 (10.3%)	13 (15.1%)	15 (9.7%)	0.419
Work in high-risk setting	33 (10.1%)	8 (9.2%)	14 (16.3%)	11 (7.1%)	0.072
Live in high-risk setting	16 (4.9%)	3 (3.5%)	6 (7.0%)	7 (4.5%)	0.537
Social vulnerability index, Mean (SD) ^b	0.43 (0.22)	0.36 (0.20)	0.44 (0.22)	0.47 (0.21)	< 0.001
Self-Reported Comorbidity					
Number of comorbidities, Mean (SD)	0.35 (0.65)	0.39 (0.62)	0.41 (0.77)	0.30 (0.59)	0.363
Asthma or Chronic Lung Disease	30 (9.2%)	11 (12.6%)	7 (8.1%)	12 (7.7%)	0.416
Cirrhosis of the liver	1 (0.3%)	0 (0.0%)	1 (1.2%)	0 (0.0%)	0.264
Immunocompromised Conditions or Weakened Immune System ^c	16 (4.9%)	0 (0.0%)	10 (11.6%)	6 (3.9%)	0.001
Diabetes	11 (3.4%)	4 (4.6%)	3 (3.5%)	4 (2.6%)	0.674
Heart Conditions or Hypertension	41 (12.5%)	14 (16.1%)	9 (10.5%)	18 (11.6%)	0.481
Overweight or obesity	16 (4.9%)	5 (5.8%)	5 (5.8%)	6 (3.9%)	0.725
At least 1 comorbidity	87 (26.5%)	28 (32.2%)	24 (27.9%)	35 (22.6%)	0.253
Index day ^d acute COVID-19 symptoms					
Number of acute COVID-19 symptoms, Mean (SD)	5.4 (2.6)	4.7 (2.5)	5.7 (2.5)	5.6 (2.6)	0.009
Systemic symptoms					
Fever	127 (38.7%)	22 (25.3%)	35 (40.7%)	70 (45.2%)	0.009
Chills	165 (50.3%)	27 (31.0%)	48 (55.8%)	90 (58.1%)	< 0.001
Muscle or Body Aches	183 (55.8%)	36 (41.4%)	52 (60.5%)	95 (61.3%)	0.007
Headache	224 (68.3%)	51 (58.6%)	62 (72.1%)	111 (71.6%)	0.077
Fatigue	204 (62.2%)	48 (55.2%)	56 (65.1%)	100 (64.5%)	0.288
Respiratory symptoms					
Shortness of Breath or Difficulty Breathing	42 (12.8%)	6 (6.9%)	13 (15.1%)	23 (14.8%)	0.157
Cough	243 (74.1%)	65 (74.7%)	63 (73.3%)	115 (74.2%)	0.976
Sore Throat	187 (57.0%)	53 (60.9%)	50 (58.1%)	84 (54.2%)	0.580
New/Recent Loss of Taste or Smell	35 (10.7%)	7 (8.1%)	13 (15.1%)	15 (9.7%)	0.276
Congestion or Runny Nose	247 (75.3%)	69 (79.3%)	72 (83.7%)	106 (68.4%)	0.018
GI symptoms					
Nausea or Vomiting	42 (12.8%)	7 (8.1%) 11 (12.8%		24 (15.5%)	0.251
Diarrhea	69 (21.0%)	14 (16.1%)	15 (17.4%)	40 (25.8%)	0.131

525 SD: Standard Deviation

^a P value refers to the comparison among Boosted, Primary and Unvaccinated.

- ^b SVI ranges from 0 to 1. A community with higher value is more socially vulnerable
- ^c Immunocompromised conditions includes compromised immune system (such as from
- 529 immuno-compromising drugs, solid organ or blood stem cell transplant, HIV, or other
- 530 conditions), conditions that result in a weakened immune system, including cancer treatment,
- and kidney failure or end stage renal disease
- 532 ^d COVID-19 test nasal swab day
- 533

	All	Boosted	Primed	Unvaccinated	P value
Month 1					
n	328	87	86	155	•
Mean (SD)	3.1 (3.6)	2.0 (2.3)	3.1 (3.5)	3.7 (4.1)	0.002
\geq 3 symptoms	130 (39.6%)	26 (29.9%)	36 (41.9%)	68 (43.9%)	0.091
General symptoms					
≥ 1 symptom	154 (47.0%)	35 (40.2%)	44 (51.2%)	75 (48,4%)	0.314
Tiredness or fatigue	135 (41.2%)	28 (32.2%)	42 (48.8%)	65 (41.9%)	0.081
Symptoms that get worse after	50 (15.2%)	8 (9.2%)	10 (11.6%)	32 (20.6%)	0.033
physical or mental activities	· · ·				
Fever	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.7%)	1.000
General pain/discomfort	50 (15.2%)	5 (5.8%)	15 (17.4%)	30 (19.4%)	0.015
Respiratory and cardiac					
≥1 symptom	142 (43.3%)	34 (39.1%)	34 (39.5%)	74 (47.7%)	0.305
Difficulty breathing or shortness of	58 (17.7%)	13 (14.9%)	13 (15.1%)	32 (20.6%)	0.412
breath					
Cough	86 (26.2%)	21 (24.1%)	19 (22.1%)	46 (29.7%)	0.385
Chest or stomach pain	32 (9.8%)	4 (4.6%)	10 (11.6%)	18 (11.6%)	0.162
Fast-beating or pounding heart	38 (11.6%)	6 (6.9%)	11 (12.8%)	21 (13.5%)	0.276
(also known as heart palpitations)					
Neurologic					
≥1 symptom	161 (49.1%)	38 (43.7%)	45 (52.3%)	78 (50.3%)	0.479
Change in smell or taste	51 (15.5%)	5 (5.8%)	14 (16.3%)	32 (20.6%)	0.009
Headache	67 (20.4%)	10 (11.5%)	18 (20.9%)	39 (25.2%)	0.040
Dizziness on standing (lightheadedness)	45 (13.7%)	7 (8.1%)	13 (15.1%)	25 (16.1%)	0.195
Difficulty thinking or concentrating (sometimes referred to as "brain fog")	86 (26.2%)	17 (19.5%)	26 (30.2%)	43 (27.7%)	0.234
Pins-and-needles feeling	24 (7.3%)	3 (3.5%)	7 (8.1%)	14 (9.0%)	0.263
Sleep problems	81 (24.7%)	14 (16.1%)	21 (24.4%)	46 (29.7%)	0.063
Mood changes	36 (11.0%)	6 (6.9%)	7 (8.1%)	23 (14.8%)	0.102
Memory loss	38 (11.6%)	4 (4.6%)	7 (8.1%)	27 (17.4%)	0.006
Other					
≥1 symptom	106 (32.3%)	19 (21.8%)	28 (32.6%)	59 (38.1%)	0.035
Diarrhea	23 (7.0%)	3 (3.5%)	3 (3.5%)	17 (11.0%)	0.036
Joint or muscle pain	66 (20.1%)	10 (11.5%)	18 (20.9%)	38 (24.5%)	0.052
Rash	11 (3.4%)	2 (2.3%)	1 (1.2%)	8 (5.2%)	0.229
Changes in period cycles	28 (11.6%)	4 (6.9%)	8 (11.8%)	16 (13.8%)	0.447
Month 3	. ,		. /	, ,	
n	292	73	77	142	

Table 2. Summary of Post-COVID-19 Symptoms at 1-, 3- and 6-month follow-up

	All	Boosted	Primed	Unvaccinated	P value
Mean (SD)	2.7 (3.5)	1.4 (1.9)	2.8 (3.5)	3.3 (4.0)	0.001
≥3 symptoms	109 (37.3%)	17 (23.3%)	32 (41.6%)	60 (42.3%)	0.016
General symptoms	· · · · · · · · · · · · · · · · · · ·				
≥1 symptom	121 (41.4%)	24 (32.9%)	32 (41.6%)	65 (45.8%)	0.192
Tiredness or fatigue	108 (37.0%)	21 (28.8%)	31 (40.3%)	56 (39.4%)	0.242
Symptoms that get worse after	36 (12.3%)	5 (6.9%)	11 (14.3%)	20 (14.1%)	0.259
physical or mental activities					
Fever	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.7%)	1.000
General pain/discomfort	43 (14.7%)	3 (4.1%)	12 (15.6%)	28 (19.7%)	0.005
Respiratory and cardiac					
≥1 symptom	83 (28.4%)	15 (20.5%)	23 (29.9%)	45 (31.7%)	0.218
Difficulty breathing or shortness of breath	42 (14.4%)	5 (6.9%)	15 (19.5%)	22 (15.5%)	0.077
Cough	38 (13.0%)	8 (11.0%)	9 (11.7%)	21 (14.8%)	0.675
Chest or stomach pain	17 (5.8%)	2 (2.7%)	5 (6.5%)	10 (7.0%)	0.470
Fast-beating or pounding heart (also known as heart palpitations)	29 (9.9%)	3 (4.1%)	9 (11.7%)	17 (12.0%)	0.149
Neurologic					
≥1 symptom	140 (47.9%)	26 (35.6%)	39 (50.6%)	75 (52.8%)	0.049
Change in smell or taste	35 (12.0%)	5 (6.9%)	9 (11.7%)	21 (14.8%)	0.236
Headache	51 (17.5%)	6 (8.2%)	14 (18.2%)	31 (21.8%)	0.044
Dizziness on standing (lightheadedness)	43 (14.7%)	3 (4.1%)	14 (18.2%)	26 (18.3%)	0.006
Difficulty thinking or concentrating (sometimes	70 (24.0%)	11 (15.1%)	15 (19.5%)	44 (31.0%)	0.020
referred to as "brain fog")					
Pins-and-needles feeling	28 (9.6%)	4 (5.5%)	9 (11.7%)	15 (10.6%)	0.377
Sleep problems	63 (21.6%)	8 (11.0%)	17 (22.1%)	38 (26.8%)	0.028
Mood changes	31 (10.6%)	2 (2.7%)	6 (7.8%)	23 (16.2%)	0.005
Memory loss	35 (12.0%)	0 (0.0%)	9 (11.7%)	26 (18.3%)	< 0.001
Other					
≥ 1 symptom	88 (30.1%)	16 (21.9%)	25 (32.5%)	47 (33.1%)	0.209
Diarrhea	18 (6.2%)	2 (2.7%)	5 (6.5%)	11 (7.8%)	0.419
Joint or muscle pain	53 (18.2%)	7 (9.6%)	15 (19.5%)	31 (21.8%)	0.083
Rash	9 (3.1%)	4 (5.5%)	0 (0.0%)	5 (3.5%)	0.091
Changes in period cycles	36 (16.7%)	5 (10.4%)	13 (22.0%)	18 (16.7%)	0.278
Month 6					
n	260	67	72	121	•
Mean (SD)	2.7 (3.7)	1.1 (1.8)	2.8 (3.6)	3.4 (4.2)	< 0.001
≥3 symptoms	91 (35.0%)	10 (14.9%)	27 (37.5%)	54 (44.6%)	< 0.001
General symptoms					

	All	Boosted	Primed	Unvaccinated	P value
≥1 symptom	112 (43.1%)	16 (23.9%)	34 (47.2%)	62 (51.2%)	0.001
Tiredness or fatigue	101 (38.8%)	15 (22.4%)	32 (44.4%)	54 (44.6%)	0.006
Symptoms that get worse after	28 (10.8%)	1 (1.5%)	8 (11.1%)	19 (15.7%)	0.005
physical or mental activities					
Fever	3 (1.2%)	0 (0.0%)	1 (1.4%)	2 (1.7%)	0.798
General pain/discomfort	36 (13.8%)	2 (3.0%)	10 (13.9%)	24 (19.8%)	0.003
Respiratory and cardiac					
≥1 symptom	68 (26.2%)	4 (6.0%)	18 (25.0%)	46 (38.0%)	< 0.001
Difficulty breathing or shortness of breath	32 (12.3%)	3 (4.5%)	7 (9.7%)	22 (18.2%)	0.017
Cough	32 (12.3%)	0 (0.0%)	9 (12.5%)	23 (19.0%)	< 0.001
Chest or stomach pain	17 (6.5%)	1 (1.5%)	4 (5.6%)	12 (9.9%)	0.073
Fast-beating or pounding heart (also known as heart palpitations)	29 (11.2%)	3 (4.5%)	7 (9.7%)	19 (15.7%)	0.057
Neurologic					
≥1 symptom	121 (46.5%)	21 (31.3%)	34 (47.2%)	66 (54.5%)	0.009
Change in smell or taste	27 (10.4%)	4 (6.0%)	8 (11.1%)	15 (12.4%)	0.398
Headache	50 (19.2%)	5 (7.5%)	16 (22.2%)	29 (24.0%)	0.017
Dizziness on standing (lightheadedness)	38 (14.6%)	7 (10.4%)	7 (9.7%)	24 (19.8%)	0.084
Difficulty thinking or concentrating (sometimes referred to as "brain fog")	58 (22.3%)	5 (7.5%)	19 (26.4%)	34 (28.1%)	0.003
Pins-and-needles feeling	27 (10.4%)	3 (4.5%)	8 (11.1%)	16 (13.2%)	0.153
Sleep problems	52 (20.0%)	3 (4.5%)	16 (22.2%)	33 (27.3%)	< 0.001
Mood changes	32 (12.3%)	3 (4.5%)	9 (12.5%)	20 (16.5%)	0.043
Memory loss	37 (14.2%)	2 (3.0%)	12 (16.7%)	23 (19.0%)	0.004
Other					
≥1 symptom	76 (29.2%)	14 (20.9%)	23 (31.9%)	39 (32.2%)	0.220
Diarrhea	14 (5.4%)	1 (1.5%)	3 (4.2%)	10 (8.3%)	0.147
Joint or muscle pain	38 (14.6%)	6 (9.0%)	12 (16.7%)	20 (16.5%)	0.314
Rash	5 (1.9%)	1 (1.5%)	0 (0.0%)	4 (3.3%)	0.323
Changes in period cycles	32 (16.8%)	8 (18.6%)	11 (20.0%)	13 (14.0%)	0.596

	Descriptive statistics	Observed		Logistic Regression			
	Descriptive statistics	Odds Ratio (95% CI)	P value	Odds Ratio (95% CI)	P value		
Base Case: ≥3 symptoms							
Boosted vs Unvaccinated	10 (14.9%) vs 54 (44.6%)	0.22 (0.10, 0.47)	< 0.001	0.36 (0.15, 0.87)	0.019		
Primed vs. Unvaccinated	27 (37.5%) vs 54 (44.6%)	0.74 (0.41, 1.35)	0.332	0.60 (0.27, 1.34)	0.296		
Boosted vs Primed	10 (14.9%) vs 27 (37.5%)	0.29 (0.13, 0.67)	0.003	0.59 (0.21, 1.65)	0.459		
Sensitivity: ≥2 symptoms							
Boosted vs Unvaccinated	14 (20.9%) vs 66 (54.5%)	0.22 (0.11, 0.44)	< 0.001	0.30 (0.13, 0.70)	0.003		
Primed vs. Unvaccinated	35 (48.6%) vs 66 (54.5%)	0.79 (0.44, 1.41)	0.425	0.64 (0.30, 1.39)	0.370		
Boosted vs Primed	14 (20.9%) vs 35 (48.6%)	0.28 (0.13, 0.59)	0.001	0.46 (0.18, 1.20)	0.140		

537	Table 3. Long COVID	Symptoms at Month 6 by	Vaccination Status:	Observed and Mode	l-based Estimates
-----	---------------------	------------------------	---------------------	-------------------	-------------------

538 Note for logistic regression model: the logistic regression model for number of post-COVID ≥3 versus <3 used GEE estimation with

539 unstructured correlation matrix. Covariates were variables for time, vaccination status and interaction of time by vaccination status, as

540 well as covariates of participant pre-COVID-19 symptom onset score, sociodemographic characteristics (age, sex, regions, social

541 vulnerability, race/ethnicity, high risk occupations), previously tested positive for COVID-19, severity of acute illness (number of

542 symptoms reported on index date), and immunocompromised status.

			Score	Change from	n pre-COVI	D-19	Relative to	Unvaccinate	ed	Relative to Primed		
		Ν	Mean (SD)	Mean (SD)	P value	ES	Mean (SD)	P value	ES	Mean (SD)	P value	ES
EQ-VAS												
Pre-COVID-19	All	130	84.9 (12.2)									
	Boosted	26	84.6 (13.5)				-1.1 (12.1)	0.692	-0.09	0.8 (12.9)	0.804	0.06
	Primed	36	83.8 (12.5)				-1.9 (11.9)	0.431	-0.16			
	Unvaccinated	68	85.7 (11.6)									
Week 4	All	123	74.2 (16.2)	-10.9 (15.6)	< 0.001	-0.67						
	Boosted	26	74.4 (18.1)	-10.2 (16.4)	0.004	-0.62	1.2 (16.8)	0.751	0.07	-1.6 (16.4)	0.713	-0.10
	Primed	33	76.0 (15.0)	-7.7 (11.8)	0.001	-0.65	2.8 (15.8)	0.406	0.18			
	Unvaccinated	64	73.1 (16.2)	-12.9 (16.8)	< 0.001	-0.77						
Month 3	All	108	76.4 (16.0)	-9.0 (15.2)	< 0.001	-0.56						
	Boosted	17	80.9 (10.4)	-3.8 (13.6)	0.266	-0.28	5.4 (16.1)	0.223	0.34	5.2 (14.4)	0.233	0.36
P	Primed	32	75.7 (16.1)	-9.7 (10.2)	< 0.001	-0.95	0.2 (16.9)	0.955	0.01			
	Unvaccinated	59	75.5 (17.3)	-10.1 (17.7)	< 0.001	-0.57						
Month 6	All	89	74.5 (17.2)	-10.0 (16.6)	< 0.001	-0.58						
	Boosted	10	80.4 (11.4)	-6.3 (11.5)	0.121	-0.55	5.5 (15.8)	0.319	0.35	8.8 (18.1)	0.200	0.48
	Primed	27	71.6 (20.0)	-11.2 (17.4)	0.003	-0.64	-3.3 (17.7)	0.439	-0.18			
	Unvaccinated	52	74.9 (16.5)	-10.0 (17.2)	< 0.001	-0.58						
EQ-5D-5L UI												
Pre-COVID-19	All	130	0.879 (0.144)									
	Boosted	26	0.910 (0.109)				0.038 (0.117)	0.163	0.32	0.039 (0.167)	0.369	0.23
	Primed	36	0.871 (0.199)				-0.001 (0.152)	0.975	-0.01			
	Unvaccinated	68	0.872 (0.120)									
Week 4	All	130	0.744 (0.196)	-0.135 (0.160)	< 0.001	-0.69						
	Boosted	26	0.827 (0.122)	-0.083 (0.126)	0.003	-0.66	0.081 (0.162)	0.032	0.50	0.036 (0.139)	0.319	0.26
	Primed	36	0.752 (0.198)	-0.119 (0.148)	< 0.001	-0.80	0.045 (0.165)	0.188	0.27			
	Unvaccinated	68	0.708 (0.209)	-0.164 (0.173)	< 0.001	-0.95						

544 Table 4. Summary of Observed EQ-5D-5L and WPAI scores by assessment time and vaccination status in long COVID subjects

			Score	Change from	n pre-COVII	D-19	Relative to Unvaccinated			Relative to Primed		
		Ν	Mean (SD)	Mean (SD)	P value	ES	Mean (SD)	P value	ES	Mean (SD)	P value	ES
Month 3	All	109	0.742 (0.236)	-0.153 (0.188)	< 0.001	-0.65						
	Boosted	17	0.877 (0.114)	-0.029 (0.114)	0.311	-0.25	0.153 (0.177)	0.002	0.86	0.136 (0.168)	0.010	0.81
	Primed	32	0.725 (0.275)	-0.165 (0.190)	< 0.001	-0.87	0.017 (0.191)	0.685	0.09			
	Unvaccinated	60	0.713 (0.230)	-0.182 (0.191)	< 0.001	-0.95						
Month 6	All	91	0.727 (0.242)	-0.156 (0.213)	< 0.001	-0.64						
	Boosted	10	0.922 (0.031)	0.001 (0.092)	0.973	0.01	0.156 (0.179)	0.014	0.87	0.218 (0.228)	0.014	0.96
	Primed	27	0.648 (0.273)	-0.217 (0.259)	< 0.001	-0.84	-0.062 (0.215)	0.225	-0.29			
	Unvaccinated	54	0.731 (0.229)	-0.155 (0.190)	< 0.001	-0.82						
Work Product	tivity Loss											
Pre-COVID-19	All	91	15.1 (24.7)									
	Boosted	19	6.6 (11.0)				-10.5 (22.4)	0.092	-0.47	-11.2 (23.5)	0.117	-0.48
	Primed	27	17.9 (29.2)				0.8 (27.0)	0.907	0.03			
	Unvaccinated	45	17.1 (25.6)									
Week 4	All	85	31.7 (25.4)	15.1 (32.8)	< 0.001	0.59						
	Boosted	17	26.8 (24.1)	19.4 (26.9)	0.010	0.72	-12.6 (25.1)	0.087	-0.50	4.3 (23.3)	0.562	0.18
	Primed	26	22.5 (22.8)	2.7 (30.1)	0.649	0.09	-16.8 (24.5)	0.008	-0.69			
	Unvaccinated	42	39.3 (25.5)	20.5 (35.4)	0.001	0.58						
Month 3	All	74	26.1 (26.6)	13.3 (35.2)	0.002	0.50						
	Boosted	11	18.2 (23.1)	11.2 (25.0)	0.170	0.45	-12.1 (25.6)	0.173	-0.47	-4.9 (26.8)	0.616	-0.18
	Primed	25	23.1 (28.2)	11.7 (40.1)	0.157	0.29	-7.2 (27.0)	0.305	-0.27			
	Unvaccinated	38	30.3 (26.2)	14.8 (35.5)	0.014	0.42						
Month 6	All	60	33.9 (26.2)	19.9 (38.0)	< 0.001	0.76						
	Boosted	6	43.1 (29.8)	31.4 (29.1)	0.057	1.08	6.5 (26.6)	0.587	0.24	15.8 (26.2)	0.203	0.60
	Primed	22	27.4 (25.3)	11.5 (41.3)	0.205	0.28	-9.3 (25.7)	0.199	-0.36			
	Unvaccinated	32	36.6 (26.1)	22.5 (37.7)	0.002	0.60						
Activity Impai	irment											
Pre-COVID-19	All	130	21.3 (29.3)									
	Boosted	26	14.2 (22.5)				-8.9 (28.3)	0.179	-0.31	-8.8 (28.2)	0.229	-0.31

			Score	Change from	m pre-COVII	D-19	Relative to	Unvaccinat	ed	Relative to Primed		
		Ν	Mean (SD)	Mean (SD)	P value	ES	Mean (SD)	P value	ES	Mean (SD)	P value	ES
	Primed	36	23.1 (31.7)				0.0 (30.7)	0.996	0.00			
	Unvaccinated	68	23.1 (30.2)									
Week 4	All	130	38.1 (25.7)	16.8 (35.6)	< 0.001	0.65						
	Boosted	26	31.2 (19.7)	16.9 (20.9)	< 0.001	0.81	-15.2 (24.4)	0.008	-0.62	3.7 (22.3)	0.528	0.16
	Primed	36	27.5 (24.1)	4.4 (34.9)	0.451	0.13	-18.8 (25.3)	< 0.001	-0.74			
	Unvaccinated	68	46.3 (26.0)	23.2 (39.0)	< 0.001	0.60						
Month 3	All	109	31.7 (28.3)	12.9 (36.6)	< 0.001	0.46						
	Boosted	17	28.2 (24.6)	14.1 (26.5)	0.044	0.53	-4.3 (27.8)	0.579	-0.15	-4.0 (28.5)	0.646	-0.14
	Primed	32	32.2 (30.4)	14.7 (37.6)	0.035	0.39	-0.3 (29.2)	0.961	-0.01			
	Unvaccinated	60	32.5 (28.6)	11.7 (38.9)	0.024	0.30						
Month 6	All	91	37.5 (27.5)	17.4 (39.2)	< 0.001	0.63						
	Boosted	10	31.0 (24.2)	27.0 (25.4)	0.010	1.06	-9.6 (27.5)	0.316	-0.35	-2.7 (26.8)	0.787	-0.10
	Primed	27	33.7 (27.6)	13.3 (37.0)	0.073	0.36	-6.9 (27.9)	0.299	-0.25			
	Unvaccinated	54	40.6 (28.0)	17.6 (42.4)	0.004	0.41						

		Score	Change from pre-COVID			Compared to	Unvacci	nated	ed Compared to Primed		
		LSE (95% CI)	LSE (95% CI)	P value	ES	LSE (95% CI)	Р	ES	LSE (95%	Р	ES
							value		CI)	value	
EQ-5D-5L: U	tility Index				-i						
Pre-COVID	Boosted	0.910 (0.109)									
(Observed),	Primed	0.871 (0.199)									
Mean (SD)	Unvaccinated	0.872 (0.120)									
Week 4	Boosted	0.830 (0.748,	-0.056 (-0.138,	0.183	-0.44	0.076 (-0.012,	0.108	0.47	0.028 (-0.069,	0.772	0.20
		0.912)	0.027)			0.164)			0.125)		
	Primed	0.802 (0.722,	-0.084 (-0.163,	0.039	-0.57	0.048 (-0.032,	0.337	0.29			
		0.881)	-0.004)			0.127)					
	Unvaccinated	0.754 (0.689, 0.820)	-0.131 (-0.197, -0.066)	< 0.001	-0.76						
Month 3	Boosted	0.910 (0.808, 1.011)	0.024 (-0.078, 0.125)	0.644	0.21	0.161 (0.046, 0.275)	0.003	0.91	0.137 (0.011, 0.263)	0.030	0.81
Pri	Primed	0.773 (0.687, 0.859)	-0.113 (-0.199, -0.027)	0.011	-0.59	0.024 (-0.070, 0.118)	0.818	0.13			
	Unvaccinated	0.749 (0.678, 0.819)	-0.137 (-0.207, -0.067)	< 0.001	-0.72						
Month 6	Boosted	0.910 (0.790, 1.030)	0.024 (-0.096, 0.144)	0.688	0.27	0.152 (0.007, 0.298)	0.038	0.85	0.202 (0.045, 0.359)	0.008	0.89
	Primed	0.708 (0.617, 0.800)	-0.178 (-0.269, -0.086)	< 0.001	-0.69	-0.050 (-0.153, 0.054)	0.497	-0.23			
	Unvaccinated	0.758 (0.685, 0.831)	-0.128 (-0.201, -0.055)	0.001	-0.67						
EQ-5D-5L: V	AS										
Pre-COVID	Boosted	84.6 (13.5)									
(Observed),	Primed	83.8 (12.5)									
Mean (SD)	Unvaccinated	85.7 (11.6)									
Week 4	Boosted	77.3 (70.2, 84.3)	-7.8 (-14.9, - 0.7)	0.032	-0.43	-0.2 (-8.0, 7.6)	0.998	-0.01	-3.4 (-12.1, 5.3)	0.618	-0.21
	Primed	80.7 (73.8, 87.6)	-4.3 (-11.3,	0.218	-0.29	3.2 (-4.0, 10.5)	0.544	0.20	,		

550 Table 5. Least-Square Mean Estimates and 95% CI of EQ-5D-5L and WPAI-GH scores in long COVID subjects

			2.6)								
	Unvaccinated	77.5 (71.8, 83.1)	-7.6 (-13.2, -	0.008	-0.47						
			2.0)								
Month 3	Boosted	82.6 (74.5, 90.6)	-2.5 (-10.5,	0.545	-0.24	2.3 (-6.5, 11.1)	0.806	0.14	3.6 (-6.2,	0.663	0.25
			5.6)						13.3)		
	Primed	79.0 (72.1, 85.9)	-6.0 (-13.0,	0.087	-0.38	-1.2 (-8.5, 6.0)	0.914	-0.07			
			0.9)								
	Unvaccinated	80.2 (74.5, 86.0)	-4.8 (-10.5,	0.099	-0.28						
			0.9)								
Month 6	Boosted	82.3 (72.3, 92.2)	-2.8 (-12.7,	0.584	-0.24	2.7 (-9.6, 14.9)	0.865	0.17	4.8 (-8.3,	0.658	0.27
	D · 1		7.2)	0.051	0.00	22(10.0	0.000	0.10	17.9)		
	Primed	77.4 (69.8, 85.1)	-7.6 (-15.2,	0.051	-0.38	-2.2 (-10.8,	0.820	-0.12			
	TT 1	70 ((72 (05 7)	(0.0)	0.070	0.22	6.4)					
	Unvaccinated	/9.6 (/3.6, 85./)	-5.4 (-11.5,	0.079	-0.33						
	D 1		0.0)								
WPAI: Work	Productivity L	OSS			-	[1	1	[1	1
Pre-COVID	Boosted	6.6 (11.0)									
(Observed),	Primed	17.9 (29.2)									
Mean (SD)	Unvaccinated	17.1 (25.6)									
Week 4	Boosted		11.8 (-4.3,			-8.2 (-25.0,			4.2 (-14.1,		
		25.5 (9.4, 41.7)	28.0)	0.149	0.49	8.7)	0.484	-0.32	22.48)	0.849	0.18
	Primed					-12.3 (-28.0,					
		21.4 (6.6, 36.2)	7.7 (-7.1, 22.5)	0.306	0.34	3.3)	0.151	-0.50			
	Unvaccinated		20.0 (7.2,								
		33.7 (20.9, 46.5)	32.8)	0.003	0.78						
Month 3	Boosted		-3.6 (-24.4,			-18.5 (-41.0,			-12.8 (-37.4,		
		10.1 (0, 30.8)	17.1)	0.728	-0.16	4.0)	0.129	-0.72	11.9)	0.437	-0.48
	Primed					-5.7 (-23.4,					
		22.8 (7.0, 38.7)	9.1 (-6.7, 25.0)	0.257	0.32	12.1)	0.725	-0.21			
	Unvaccinated		14.8 (0.3,								
		28.5 (14.1, 43.0)	29.3)	0.045	0.57						
Month 6	Boosted		28.9 (4.5,			7.89 (-21.3,			15.9 (-15.1,		
		42.6 (18.2, 67.0)	53.3)	0.021	0.97	37.1)	0.796	0.30	47.0)	0.442	0.61
	Primed		12.9 (-4.0,			-8.1 (-28.0,					
		26.7 (9.7, 43.6)	29.8)	0.132	0.51	11.9)	0.604	-0.31			

	Unvaccinated		21.0 (6.4,								
		34.7 (20.1, 49.3)	35.6)	0.005	0.81						
WPAI: Activ	ity Impairment										
Pre-COVID	Boosted	14.2 (22.5)									
(Observed),	Primed	23.1 (31.7)									
Mean (SD)	Unvaccinated	23.1 (30.2)									
Week 4	Boosted					-13.0 (-26.1,			6.9 (-7.4,		
		25.7 (14.1, 37.4)	5.6 (-6.1, 17.3)	0.346	0.28	0.1)	0.053	-0.53	21.3)	0.489	0.31
	Primed		-1.3 (-12.5,			-19.9 (-31.6, -					
		18.8 (7.7, 30.0)	9.8)	0.813	-0.06	8.2)	< 0.001	-0.79			
	Unvaccinated		18.6 (9.3,								
		38.7 (29.5, 47.9)	27.8)	< 0.001	0.71						
Month 3	Boosted		-2.3 (-18.1,			-7.1 (-25.6,			-5.4 (-25.8,		
		17.8 (2.0, 33.6)	13.4)	0.770	-0.10	11.4)	0.635	-0.26	14.9)	0.802	-0.19
	Primed					-1.7 (-16.6,					
		23.3 (10.5, 36.0)	3.1 (-9.7, 15.9)	0.632	0.10	13.2)	0.963	-0.06			
	Unvaccinated	24.9 (14.6, 35.3)	4.8 (-5.6, 15.1)	0.365	0.17						
Month 6	Boosted					-4.6 (-27.9,			5.3 (-19.6,		
		29.8 (11.2, 48.4)	9.6 (-9.0, 28.3)	0.308	0.40	18.6)	0.885	-0.17	30.2)	0.870	0.20
	Primed					-9.9 (-25.7,					
		24.5 (11.1, 37.9)	4.4 (-9.0, 17.7)	0.521	0.16	5.9)	0.301	-0.36			
	Unvaccinated		14.3 (3.8,								
		34.4 (24.0, 44.9)	24.7)	0.008	0.51						

551 Note: Mixed models for repeated measurements with unstructured correlation matrix include variables for time, vaccination status and

552 interaction of time by vaccination status, as well as covariates of participant pre-COVID-19 symptom onset score, sociodemographic

553 characteristics (age, sex, regions, social vulnerability, race/ethnicity, high risk occupations), previously tested positive for COVID-19,

severity of acute illness (number of symptoms reported on index date), and immunocompromised status.



556 Figure 1. Trajectory of prevalence of long COVID over time, by vaccination status and type

565 Supplemental Material

566 Supplemental Figure 1 Study Flow Chart



568

569 Supplemental Figure 2 Questionnaire on long COVID symptoms

Do you experience the following Ongoing COVID-related symptoms or NEW symptoms TODAY that you did not have before your participation in this survey study? (Check all that apply)

General symptoms Tiredness or fatigue Symptoms that get worse after physical or mental activities Fever General pain/discomfort
Respiratory and Cardiac Difficulty breathing or shortness of breath Cough Chest or stomach pain Fast-beating or pounding heart (also known as heart palpitations)
Neurologic Change in smell or taste Headache Dizziness on standing (lightheadedness) Difficulty thinking or concentrating (sometimes referred to as "brain fog") Pins-and-needles feeling Sleep problems Mood changes Memory loss
Other Diarrhea Joint or muscle pain Rash Changes in period cycles (women)

571 Source: Centers for Disease Control and Prevention. Long COVID or Post-COVID Conditions.

- 572 <u>https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html</u> Accessed August 15,
- 573 2022.
- 574



575 Supplemental Figure 3 Prevalence of long COVID symptoms by vaccination status

(b) Month 3





588 Supplemental Figure 4 Number of symptoms over time by vaccination status



591 Week 4, Month 3 and Month 6, data collection was based on 20 long COVID symptoms.



593 Supplemental Figure 5 Absence of long COVID symptoms by vaccination status594